Cadila Pharmaceuticals is taking the lead in the race of fight against COVID-19 through its research breakthrough of immunomodulator. The company has recently tested the immunomodulator successfully in four COVID positive patients.
The development of the immunomodulator by Cadila was carried out in partnership with our country’s premier research organization – Council of Scientific and Industrial Research (CSIR). Phase -3 trials for the immunomodulator has been completed successfully and soon it will be available in the market (within 2 months) to treat the COVID-19 patients. The company based in Ahmedabad is ready to start large scale manufacturing at the facility in Dholka if everything goes as planned.
The immunomodulator, named Sepsivac will be repurposed for use against COVID-19. Earlier, it has been used for the treatment of leprosy and was considered to be highly robust for gram-negative sepsis patients.
Soon the drug will enter into human trials as it has received a green light from the Drug Controller General of India (DCGI). The trail will be conducted among more than 4000 people prone to the disease. Mycobacterium indicus pranii will be used in the immunomodulator as it is widely known for prompting several immune responses.
To know more about origin, virology of COVID-19, Click here
To know more about emerging themes in COVID-19, Click here
To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com
Want to set up an online consultation for your practice, Click here